A Phase 1 interventional study of LY3502970 and Placebo in Healthy, sponsored by Eli Lilly and Company. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-10.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The main purposes of this study are to determine:
This study has 5 parts (A, B, C, D, and E). Parts A and D involve a single dose of LY3502970 and will last about 15 days. Part B and E involve multiple doses of LY3502970 and will last about 4 weeks. Part C involves two single doses of LY3502970 and will last about 29 days. Each participant will enroll in only one part. Screening must be completed within 28 days before study start. This study is for research purposes only, and is not intended to treat any medical condition.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received a single oral dose of 0.3 milligram (mg) LY3502970.
Drug: LY3502970
Participants received a single oral dose of 1 mg LY3502970.
Drug: LY3502970
Participants received a single oral dose of 3 mg LY3502970.
Drug: LY3502970
Participants received a single oral dose of 6 mg LY3502970.
Drug: LY3502970
Participants received a single oral dose of Placebo.
Drug: Placebo
Participants received oral doses of placebo once daily for 4 weeks.
Drug: Placebo
Participants received oral doses of 2 mg LY3502970 once daily for 4 weeks.
Drug: LY3502970
Participants received oral doses of LY3502970 once daily for 4 weeks where 2 mg was given for first week, 4 mg for second week followed by 6 mg on the third and fourth week.
Drug: LY3502970
Participants received oral doses of LY3502970 once daily for 4 weeks where 2 mg was given for first week, 4 mg for second week, 8 mg for third week and 16 mg for fourth week.
Drug: LY3502970
Participants received oral doses of LY3502970 once daily for 4 weeks, where 2 mg was given on first week, 5 mg on second week, 12 mg on third week and 24 mg on fourth week. On day 27, midazolam 200 microgram (mcg) was coadministered with 24 mg LY3502970, and 40 mg atorvastatin administered 4 hours after midazolam.
Drug: LY3502970 · Drug: Atorvastatin · Drug: Midazolam
Participants received oral doses of LY3502970 once daily for 4 weeks, where 2 mg was given on first week, 5 mg on second week, 12 mg on third week and 24 mg on fourth week. On day 27, 20 mg simvastatin was coadministered with 24 mg LY3502970.
Drug: LY3502970 · Drug: Simvastatin
Part C of the study is exploratory, conducted to study exploratory objectives. Participants received a single oral dose of 3 mg LY3502970 in treatment period 1 (fasted condition), followed by administration in treatment period 2 (fed condition), with a washout period of at least 5 days between periods.
Drug: LY3502970
Part C of the study is exploratory, conducted to study exploratory objectives. Participants received a single oral dose of 3 mg LY3502970 in treatment period1 (fed condition), followed by administration in treatment period 2 (fasted condition), with a washout period of at least 5 days between periods.
Drug: LY3502970
Part D of the study is exploratory, conducted to study exploratory objectives. Participants received a single oral dose of 3 mg LY3502970 in a controlled-release prototype formulation.
Drug: LY3502970
Part D of the study is exploratory, conducted to study exploratory objectives. Participants received a single oral dose of placebo in a controlled-release prototype formulation.
Drug: Placebo
Part E of the study is exploratory, conducted to study exploratory objectives. Participants received oral doses of LY3502970 once daily for 4 weeks where 2 mg was given for first week, 5 mg for second week, 12 mg for third week and 24 mg as formulation 1 for the fourth week.
Drug: LY3502970
Part E of the study is exploratory, conducted to study exploratory objectives. Participants received oral doses of LY3502970 once daily for 4 weeks where 2 mg was given for first week, 5 mg for second week, 12 mg for third week and 24 mg as formulation 2 for the fourth week.
Drug: LY3502970
Administered orally.
Administered orally.
Administered orally.
Administered orally.
Administered orally.
Parts A and B: Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug
An SAE is any adverse event from this study that results in 1 of the following: Death, initial or prolonged inpatient hospitalization, a life-threatening experience (that is, immediate risk of dying), persistent or significant disability/incapacity, congenital anomaly/birth defect, important medical events that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the subject or may require intervention to prevent 1 of the other outcomes listed in the definition above. The number of participants with one or more SAEs considered by the investigator to be related to study drug administration is reported. An overall summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module.
Time frame: Baseline through Follow-up (up to Day 42)
Part A: Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of LY3502970
PK: Cmax of LY3502970
Time frame: Pre-dose, 0.5, 1, 2, 4, 8, 12, 16, 24, 48, 72, 96 hours post-dose
Part A: PK: Area Under the Concentration Versus Time Curve From Time Zero to the Last Measurable Concentration (AUC[0-tlast]) of LY3502970
PK: AUC(0-tlast) of LY3502970
Time frame: Pre-dose, 0.5, 1, 2, 4, 8, 12, 16, 24, 48, 72, 96 hours post-dose
Part A: PK: Time of Maximum Observed Concentration (Tmax) of LY3502970
PK: Tmax of LY3502970
Time frame: Pre-dose, 0.5, 1, 2, 4, 8, 12, 16, 24, 48, 72, 96 hours post-dose
Part B: PK: Maximum Observed Concentration (Cmax) of LY3502970 on Day 1
PK: Cmax of LY3502970
Time frame: Day 1 (pre-dose, 0.5, 1, 2, 4, 8, 12, 16, 24 hours post-dose)
Part B: PK: Maximum Observed Concentration (Cmax) of LY3502970 on Day 28
PK: Cmax of LY3502970
Time frame: Day 28 (pre-dose, 0.5, 1, 2, 4, 8, 12, 16, 24, 36, 96, 168, 336 hours post-dose)
Part B: PK: Area Under the Concentration Versus Time Curve From Time Zero to the Last Measurable Concentration (AUC[0-tlast]) of LY3502970 on Day 1
PK: AUC(0-tlast) of LY3502970
Time frame: Day 1 (pre-dose, 0.5, 1, 2, 4, 8, 12, 16, 24 hours post-dose)
Part B: PK: Area Under the Concentration Versus Time Curve From Time Zero to the Last Measurable Concentration (AUC[0-tlast]) of LY3502970 on Day 28
PK: AUC(0-tlast) of LY3502970
Time frame: Day 28 (pre-dose, 0.5, 1, 2, 4, 8, 12, 16, 24, 36, 96, 168, 336 hours post-dose)
Part B: PK: Time of Maximum Observed Concentration (Tmax) of LY3502970 on Day 1
PK: Tmax of LY3502970
Time frame: Day 1 (pre-dose, 0.5, 1, 2, 4, 8, 12, 16, 24 hours post-dose)
Part B: PK: Time of Maximum Observed Concentration (Tmax) of LY3502970 on Day 28
PK: Tmax of LY3502970
Time frame: Day 28 (pre-dose, 0.5, 1, 2, 4, 8, 12, 16, 24, 36, 96, 168, 336 hours post-dose)
| Milestone | Part A Placebo | Part A 0.3 mg LY3502970 | Part A 1 mg LY3502970 | Part A 3 mg LY3502970 | Part A 6 mg LY3502970 | Part B Placebo | Part B: 2 mg LY3502970 (Cohort G) | Part B: 2 / 4 / 6 mg LY3502970 (Cohort H) | Part B: 2 / 4 / 8 / 16 mg LY3502970 (Cohort I) | Part B: 2 / 5 / 12 / 24 mg LY3502970 (Cohort J) | Part B: 2 / 5 / 12 / 24 mg LY3502970 (Cohort K) | Part C: 3 mg LY3502970 (Fasted/Fed) | Part C: 3 mg LY3502970 (Fed/Fasted) | Part D: 3 mg LY3502970 Prototype Formulation | Part D: Placebo Prototype Formulation | Part E: 2 / 5 / 12 / 24 mg LY3502970 (24 mg as Formulation 1) | Part E: 2 / 5 / 12 / 24 mg LY3502970 (24 mg as Formulation 2) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 8 | 6 | 6 | 6 | 6 | 15 | 9 | 9 | 9 | 9 | 9 | 6 | 6 | 6 | 2 | 11 | 10 |
| Received at least one dose of study drug | 8 | 6 | 6 | 6 | 6 | 15 | 9 | 9 | 9 | 9 | 9 | 6 | 6 | 6 | 2 | 11 | 10 |
| Completed | 8 | 6 | 6 | 4 | 6 | 13 | 8 | 8 | 7 | 9 | 8 | 6 | 6 | 5 | 2 | 9 | 10 |
| Not completed | 0 | 0 | 0 | 2 | 0 | 2 | 1 | 1 | 2 | 0 | 1 | 0 | 0 | 1 | 0 | 2 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 2 | 0 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
An SAE is any adverse event from this study that results in 1 of the following: Death, initial or prolonged inpatient hospitalization, a life-threatening experience (that is, immediate risk of dying), persistent or significant disability/incapacity, congenital anomaly/birth defect, important medical events that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the subject or may require intervention to prevent 1 of the other outcomes listed in the definition above. The number of participants with one or more SAEs considered by the investigator to be related to study drug administration is reported. An overall summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module.
| Participants | Part A Placebo | Part A 0.3 mg LY3502970 | Part A 1 mg LY3502970 | Part A 3 mg LY3502970 | Part A 6 mg LY3502970 | Part B Placebo | Part B: 2 mg LY3502970 | Part B: 4 mg LY3502970 | Part B: 5 mg LY3502970 | Part B: 6 mg LY3502970 | Part B: 8 mg LY3502970 | Part B: 12 mg LY3502970 | Part B: 16 mg LY3502970 | Part B: 24 mg LY3502970 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Parts A and B: Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PK: Cmax of LY3502970
| Nanograms per milliliter (ng/mL) | Part A 0.3 mg LY3502970 | Part A 1 mg LY3502970 | Part A 3 mg LY3502970 | Part A 6 mg LY3502970 |
|---|---|---|---|---|
| Part A: Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of LY3502970 | 1.45 ± 48 | 4.02 ± 36 | 14.9 ± 20 | 12.9 ± 43 |
PK: AUC(0-tlast) of LY3502970
| nanograms*hours per milliliter (ng*h/mL) | Part A 0.3 mg LY3502970 | Part A 1 mg LY3502970 | Part A 3 mg LY3502970 | Part A 6 mg LY3502970 |
|---|---|---|---|---|
| Part A: PK: Area Under the Concentration Versus Time Curve From Time Zero to the Last Measurable Concentration (AUC[0-tlast]) of LY3502970 | 34.0 ± 41 | 89.1 ± 54 | 362 ± 28 | 440 ± 8 |
PK: Tmax of LY3502970
| hours | Part A 0.3 mg LY3502970 | Part A 1 mg LY3502970 | Part A 3 mg LY3502970 | Part A 6 mg LY3502970 |
|---|---|---|---|---|
| Part A: PK: Time of Maximum Observed Concentration (Tmax) of LY3502970 | 8 (4.05 to 16.15) | 4.05 (4.05 to 8) | 6.04 (4.05 to 8) | 12.04 (8.07 to 16.02) |
PK: Cmax of LY3502970
| ng/mL | Part B: 2 mg LY3502970 (Cohorts G-K). |
|---|---|
| Part B: PK: Maximum Observed Concentration (Cmax) of LY3502970 on Day 1 | 8.40 ± 33 |
PK: Cmax of LY3502970
| ng/mL | Part B: 2 mg LY3502970 (Cohort G) | Part B: 6 mg LY3502970 (Cohort H) | Part B: 16 mg LY3502970 (Cohort I) | Part B: 24 mg LY3502970 (Cohorts J, K) |
|---|---|---|---|---|
| Part B: PK: Maximum Observed Concentration (Cmax) of LY3502970 on Day 28 | 11.1 ± 36 | 34.4 ± 23 | 68.2 ± 51 | 99.6 ± 92 |
PK: AUC(0-tlast) of LY3502970
| ng*h/mL | Part B: 2 mg LY3502970 (Cohorts G-K). |
|---|---|
| Part B: PK: Area Under the Concentration Versus Time Curve From Time Zero to the Last Measurable Concentration (AUC[0-tlast]) of LY3502970 on Day 1 | 118 ± 29 |
PK: AUC(0-tlast) of LY3502970
| ng*h/mL | Part B: 2 mg LY3502970 (Cohort G) | Part B: 6 mg LY3502970 (Cohort H) | Part B: 16 mg LY3502970 (Cohort I) | Part B: 24 mg LY3502970 (Cohorts J, K) |
|---|---|---|---|---|
| Part B: PK: Area Under the Concentration Versus Time Curve From Time Zero to the Last Measurable Concentration (AUC[0-tlast]) of LY3502970 on Day 28 | 428 ± 43 | 1300 ± 68 | 3080 ± 60 | 3490 ± 90 |
PK: Tmax of LY3502970
| hours | Part B: 2 mg LY3502970 (Cohorts G-K). |
|---|---|
| Part B: PK: Time of Maximum Observed Concentration (Tmax) of LY3502970 on Day 1 | 8 (3.92 to 12.02) |
PK: Tmax of LY3502970
| hours | Part B: 2 mg LY3502970 (Cohort G) | Part B: 6 mg LY3502970 (Cohort H) | Part B: 16 mg LY3502970 (Cohort I) | Part B: 24 mg LY3502970 (Cohorts J, K) |
|---|---|---|---|---|
| Part B: PK: Time of Maximum Observed Concentration (Tmax) of LY3502970 on Day 28 | 4.08 (2.00 to 8.00) | 8.00 (4.07 to 12.17) | 6.06 (2.00 to 12.13) | 8.08 (0.00 to 24.00) |
Collected over Baseline through Follow-up (up to Day 42). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part A Placebo | 0/8 (0%) | 0/8 (0%) | 1/8 (12.5%) |
| Part A 0.3 mg LY3502970 | 0/6 (0%) | 0/6 (0%) | 1/6 (16.7%) |
| Part A 1 mg LY3502970 | 0/6 (0%) | 0/6 (0%) | 1/6 (16.7%) |
| Part A 3 mg LY3502970 | 0/6 (0%) | 0/6 (0%) | 3/6 (50%) |
| Part A 6 mg LY3502970 | 0/6 (0%) | 0/6 (0%) | 5/6 (83.3%) |
| Part B Placebo QD | 0/15 (0%) | 0/15 (0%) | 4/15 (26.7%) |
| Part B 2 mg LY3502970 QD | 0/45 (0%) | 0/45 (0%) | 16/45 (35.6%) |
| Part B 4 mg LY3502970 QD | 0/18 (0%) | 0/18 (0%) | 8/18 (44.4%) |
| Part B 5 mg LY3502970 QD | 0/17 (0%) | 0/17 (0%) | 6/17 (35.3%) |
| Part B 6 mg LY3502970 QD | 0/8 (0%) | 0/8 (0%) | 5/8 (62.5%) |
| Part B 8 mg LY3502970 QD | 0/9 (0%) | 0/9 (0%) | 6/9 (66.7%) |
| Part B 12 mg LY3502970 QD | 0/17 (0%) | 0/17 (0%) | 8/17 (47.1%) |
| Part B 16 mg LY3502970 QD | 0/8 (0%) | 0/8 (0%) | 2/8 (25%) |
| Part B 24 mg LY3502970 QD | 0/17 (0%) | 0/17 (0%) | 9/17 (52.9%) |
| Part C 3 mg LY3502970 Fasted | 0/12 (0%) | 0/12 (0%) | 2/12 (16.7%) |
| Part C 3 mg LY3502970 Fed | 0/12 (0%) | 0/12 (0%) | 0/12 (0%) |
| Part D: 3 mg LY3502970 Prototype Formulation | 0/6 (0%) | 0/6 (0%) | 2/6 (33.3%) |
| Part D: Placebo Prototype Formulation | 0/2 (0%) | 0/2 (0%) | 0/2 (0%) |
| Part E 2 mg LY3502970 QD | 0/21 (0%) | 0/21 (0%) | 4/21 (19%) |
| Part E 5 mg LY3502970 QD | 0/20 (0%) | 0/20 (0%) | 4/20 (20%) |
| Part E 12 mg LY3502970 QD | 0/19 (0%) | 0/19 (0%) | 6/19 (31.6%) |
| Part E 24 mg LY3502970 QD | 0/19 (0%) | 0/19 (0%) | 5/19 (26.3%) |
| Part E 24 mg LY3502970 Formulation 1 QD | 0/9 (0%) | 0/9 (0%) | 0/9 (0%) |
| Part E 24 mg LY3502970 Formulation 2 QD | 0/10 (0%) | 0/10 (0%) | 1/10 (10%) |
| Event | Part A Placebo | Part A 0.3 mg LY3502970 | Part A 1 mg LY3502970 | Part A 3 mg LY3502970 | Part A 6 mg LY3502970 | Part B Placebo QD | Part B 2 mg LY3502970 QD | Part B 4 mg LY3502970 QD | Part B 5 mg LY3502970 QD | Part B 6 mg LY3502970 QD | Part B 8 mg LY3502970 QD | Part B 12 mg LY3502970 QD | Part B 16 mg LY3502970 QD | Part B 24 mg LY3502970 QD | Part C 3 mg LY3502970 Fasted | Part C 3 mg LY3502970 Fed | Part D: 3 mg LY3502970 Prototype Formulation | Part D: Placebo Prototype Formulation | Part E 2 mg LY3502970 QD | Part E 5 mg LY3502970 QD | Part E 12 mg LY3502970 QD | Part E 24 mg LY3502970 QD | Part E 24 mg LY3502970 Formulation 1 QD | Part E 24 mg LY3502970 Formulation 2 QD |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| VomitingGastrointestinal disorders | 0/8 | 0/6 | 0/6 | 3/6 | 4/6 | 0/15 | 2/45 | 0/18 | 0/17 | 0/8 | 1/9 | 1/17 | 0/8 | 3/17 | 1/12 | 0/12 | 0/6 | 0/2 | 3/21 | 0/20 | 3/19 | 1/19 | 0/9 | 1/10 |
| NauseaGastrointestinal disorders | 0/8 | 0/6 | 0/6 | 3/6 | 3/6 | 0/15 | 5/45 | 4/18 | 1/17 | 4/8 | 3/9 | 3/17 | 1/8 | 2/17 | 2/12 | 0/12 | 1/6 | 0/2 | 2/21 | 1/20 | 4/19 | 3/19 | 0/9 | 1/10 |
| HeadacheNervous system disorders | 0/8 | 0/6 | 1/6 | 0/6 | 2/6 | 0/15 | 3/45 | 4/18 | 1/17 | 3/8 | 0/9 | 4/17 | 0/8 | 5/17 | 1/12 | 0/12 | 1/6 | 0/2 | 1/21 | 1/20 | 2/19 | 1/19 | 0/9 | 0/10 |
| ConstipationGastrointestinal disorders | 0/8 | 0/6 | 0/6 | 0/6 | 0/6 | 0/15 | 5/45 | 6/18 | 3/17 | 1/8 | 2/9 | 2/17 | 0/8 | 2/17 | 0/12 | 0/12 | 1/6 | 0/2 | 0/21 | 1/20 | 0/19 | 0/19 | 0/9 | 0/10 |
| Abdominal distensionGastrointestinal disorders | 0/8 | 0/6 | 0/6 | 0/6 | 0/6 | 0/15 | 1/45 | 0/18 | 0/17 | 0/8 | 0/9 | 1/17 | 0/8 | 1/17 | 0/12 | 0/12 | 1/6 | 0/2 | 1/21 | 0/20 | 0/19 | 1/19 | 0/9 | 0/10 |
| Abdominal painGastrointestinal disorders | 0/8 | 0/6 | 0/6 | 0/6 | 1/6 | 0/15 | 6/45 | 1/18 | 0/17 | 1/8 | 0/9 | 0/17 | 0/8 | 1/17 | 0/12 | 0/12 | 0/6 | 0/2 | 1/21 | 0/20 | 0/19 | 0/19 | 0/9 | 0/10 |
| Abdominal pain lowerGastrointestinal disorders | 0/8 | 0/6 | 0/6 | 0/6 | 0/6 | 0/15 | 0/45 | 0/18 | 0/17 | 0/8 | 0/9 | 0/17 | 0/8 | 0/17 | 0/12 | 0/12 | 1/6 | 0/2 | 0/21 | 0/20 | 0/19 | 0/19 | 0/9 | 0/10 |
| HaematocheziaGastrointestinal disorders | 0/8 | 0/6 | 0/6 | 0/6 | 1/6 | 0/15 | 0/45 | 0/18 | 0/17 | 0/8 | 0/9 | 0/17 | 0/8 | 0/17 | 0/12 | 0/12 | 0/6 | 0/2 | 0/21 | 0/20 | 0/19 | 0/19 | 0/9 | 0/10 |
| Electrocardiogram t wave inversionInvestigations | 0/8 | 0/6 | 0/6 | 0/6 | 1/6 | 0/15 | 0/45 | 0/18 | 0/17 | 0/8 | 0/9 | 0/17 | 0/8 | 0/17 | 0/12 | 0/12 | 0/6 | 0/2 | 0/21 | 0/20 | 0/19 | 0/19 | 0/9 | 0/10 |
| Decreased appetiteMetabolism and nutrition disorders | 0/8 | 0/6 | 0/6 | 0/6 | 1/6 | 0/15 | 4/45 | 1/18 | 1/17 | 1/8 | 1/9 | 0/17 | 0/8 | 0/17 | 0/12 | 0/12 | 0/6 | 0/2 | 2/21 | 0/20 | 2/19 | 0/19 | 0/9 | 0/10 |
All enrolled participants.
| Age, Categorical(Participants) | Part A Placebo | Part A 0.3 mg LY3502970 | Part A 1 mg LY3502970 | Part A 3 mg LY3502970 | Part A 6 mg LY3502970 | Part B Placebo | Part B: 2 mg LY3502970 (Cohort G) | Part B: 2 / 4 / 6 mg LY3502970 (Cohort H) | Part B: 2 / 4 / 8 / 16 mg LY3502970 (Cohort I) | Part B: 2 / 5/ 12 / 24 mg LY3502970 (Cohort J) | Part B: 2 / 5/ 12 / 24 mg LY3502970 (Cohort K) | Part C: 3 mg LY3502970 (Fasted/Fed) | Part C: 3 mg LY3502970 (Fed/Fasted) | Part D: 3 mg LY3502970 Prototype Formulation | Part D: Placebo Prototype Formulation | Part E: 2 / 5 / 12 / 24 mg LY3502970 (24 mg as Formulation 1) | Part E: 2 / 5 / 12 / 24 mg LY3502970 (24 mg as Formulation 2) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 8 | 6 | 6 | 6 | 6 | 15 | 9 | 9 | 9 | 9 | 9 | 6 | 6 | 6 | 2 | 11 | 10 | 133 |
| >=65 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Part A Placebo | Part A 0.3 mg LY3502970 | Part A 1 mg LY3502970 | Part A 3 mg LY3502970 | Part A 6 mg LY3502970 | Part B Placebo | Part B: 2 mg LY3502970 (Cohort G) | Part B: 2 / 4 / 6 mg LY3502970 (Cohort H) | Part B: 2 / 4 / 8 / 16 mg LY3502970 (Cohort I) | Part B: 2 / 5/ 12 / 24 mg LY3502970 (Cohort J) | Part B: 2 / 5/ 12 / 24 mg LY3502970 (Cohort K) | Part C: 3 mg LY3502970 (Fasted/Fed) | Part C: 3 mg LY3502970 (Fed/Fasted) | Part D: 3 mg LY3502970 Prototype Formulation | Part D: Placebo Prototype Formulation | Part E: 2 / 5 / 12 / 24 mg LY3502970 (24 mg as Formulation 1) | Part E: 2 / 5 / 12 / 24 mg LY3502970 (24 mg as Formulation 2) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 2 | 3 | 3 | 1 | 4 | 3 | 3 | 2 | 4 | 0 | 4 | 1 | 3 | 2 | 1 | 1 | 1 | 38 |
| Male | 6 | 3 | 3 | 5 | 2 | 12 | 6 | 7 | 5 | 9 | 5 | 5 | 3 | 4 | 1 | 10 | 9 | 95 |
| Ethnicity (NIH/OMB)(Participants) | Part A Placebo | Part A 0.3 mg LY3502970 | Part A 1 mg LY3502970 | Part A 3 mg LY3502970 | Part A 6 mg LY3502970 | Part B Placebo | Part B: 2 mg LY3502970 (Cohort G) | Part B: 2 / 4 / 6 mg LY3502970 (Cohort H) | Part B: 2 / 4 / 8 / 16 mg LY3502970 (Cohort I) | Part B: 2 / 5/ 12 / 24 mg LY3502970 (Cohort J) | Part B: 2 / 5/ 12 / 24 mg LY3502970 (Cohort K) | Part C: 3 mg LY3502970 (Fasted/Fed) | Part C: 3 mg LY3502970 (Fed/Fasted) | Part D: 3 mg LY3502970 Prototype Formulation | Part D: Placebo Prototype Formulation | Part E: 2 / 5 / 12 / 24 mg LY3502970 (24 mg as Formulation 1) | Part E: 2 / 5 / 12 / 24 mg LY3502970 (24 mg as Formulation 2) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 5 | 1 | 1 | 1 | 2 | 5 | 2 | 5 | 2 | 2 | 5 | 2 | 2 | 1 | 1 | 3 | 1 | 41 |
| Not Hispanic or Latino | 3 | 5 | 5 | 5 | 4 | 10 | 7 | 4 | 7 | 7 | 4 | 4 | 4 | 5 | 1 | 8 | 9 | 92 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Part A Placebo | Part A 0.3 mg LY3502970 | Part A 1 mg LY3502970 | Part A 3 mg LY3502970 | Part A 6 mg LY3502970 | Part B Placebo | Part B: 2 mg LY3502970 (Cohort G) | Part B: 2 / 4 / 6 mg LY3502970 (Cohort H) | Part B: 2 / 4 / 8 / 16 mg LY3502970 (Cohort I) | Part B: 2 / 5/ 12 / 24 mg LY3502970 (Cohort J) | Part B: 2 / 5/ 12 / 24 mg LY3502970 (Cohort K) | Part C: 3 mg LY3502970 (Fasted/Fed) | Part C: 3 mg LY3502970 (Fed/Fasted) | Part D: 3 mg LY3502970 Prototype Formulation | Part D: Placebo Prototype Formulation | Part E: 2 / 5 / 12 / 24 mg LY3502970 (24 mg as Formulation 1) | Part E: 2 / 5 / 12 / 24 mg LY3502970 (24 mg as Formulation 2) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 4 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 2 | 3 | 0 | 0 | 8 | 4 | 3 | 2 | 4 | 3 | 0 | 3 | 4 | 0 | 6 | 5 | 48 |
| White | 7 | 3 | 3 | 6 | 6 | 7 | 4 | 6 | 7 | 3 | 6 | 5 | 3 | 2 | 2 | 4 | 4 | 78 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 3 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Part A Placebo | Part A 0.3 mg LY3502970 | Part A 1 mg LY3502970 | Part A 3 mg LY3502970 | Part A 6 mg LY3502970 | Part B Placebo | Part B: 2 mg LY3502970 (Cohort G) | Part B: 2 / 4 / 6 mg LY3502970 (Cohort H) | Part B: 2 / 4 / 8 / 16 mg LY3502970 (Cohort I) | Part B: 2 / 5/ 12 / 24 mg LY3502970 (Cohort J) | Part B: 2 / 5/ 12 / 24 mg LY3502970 (Cohort K) | Part C: 3 mg LY3502970 (Fasted/Fed) | Part C: 3 mg LY3502970 (Fed/Fasted) | Part D: 3 mg LY3502970 Prototype Formulation | Part D: Placebo Prototype Formulation | Part E: 2 / 5 / 12 / 24 mg LY3502970 (24 mg as Formulation 1) | Part E: 2 / 5 / 12 / 24 mg LY3502970 (24 mg as Formulation 2) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | 8 | 6 | 6 | 6 | 6 | 15 | 9 | 9 | 9 | 9 | 9 | 6 | 6 | 6 | 2 | 11 | 10 | 133 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jun 2019 to primary completion in Nov 2020, 16 months.
Results were first posted in Jul 2026, 5 years 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Orforglipron